Aankondiging • Mar 04
AbClon Inc., Annual General Meeting, Mar 23, 2026 AbClon Inc., Annual General Meeting, Mar 23, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 30, eunhaeng-ro, yeongdeungpo-gu, seoul South Korea New Risk • Nov 24
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 20% per year over the past 5 years. Minor Risk Revenue is less than US$5m (₩3.8b revenue, or US$2.6m). Reported Earnings • Nov 12
Third quarter 2025 earnings released: ₩184 loss per share (vs ₩198 loss in 3Q 2024) Third quarter 2025 results: ₩184 loss per share. Revenue: ₩1.57b (up 96% from 3Q 2024). Net loss: ₩3.52b (loss widened 2.8% from 3Q 2024). Aankondiging • Oct 03
AbClon Inc. announced that it expects to receive KRW 10.799952065 billion in funding from Paratus Investment Inc., Dongyu Investment Co., Ltd, Winvest Venture Capital AbClon Inc. announced private placement of 592,655 convertible preferred shares at a price of KRW 18,223 for gross proceeds of KRW 10,799,952,065 on October 1, 2025. The transaction includes participation from DSC Home Run Fund No. 2 for 214,015 shares, DSC Dominance Fund I for 32,925 shares, Paratus Innovation Growth M&A No. 2 for 246,940 shares, Dongyu Investment Co Ltd. for 49,388 shares, Alpha View Partners Co., Ltd. for 32,925 shares, Winvest Venture Capital for 16,462 shares. The preferred shares are 100% convertible into 592,655 shares at a conversion price of KRW 18,223 from conversion period of November 7, 2026 to October 28, 2030. The preferred dividend rate for the company’s preferred stock is 1.0% per annum. The shares have a restriction period of 1 year. The transaction is expected to close on October 28, 2025. The transaction is approved by board of directors of the company. New Risk • Sep 29
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩15b free cash flow). Earnings have declined by 22% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Revenue is less than US$5m (₩3.0b revenue, or US$2.2m). New Risk • Aug 19
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩15b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩15b free cash flow). Earnings have declined by 22% per year over the past 5 years. Minor Risk Revenue is less than US$5m (₩3.0b revenue, or US$2.2m). Aankondiging • May 20
AbClon Inc. announced that it has received KRW 12.2122 billion in funding from Chong Kun Dang Pharmaceutical Corp. On May 19, 2025, AbClon Inc. closed the transaction. New Risk • May 10
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 28% per year over the past 5 years. Minor Risk Revenue is less than US$5m (₩2.3b revenue, or US$1.7m). Aankondiging • May 09
AbClon Inc. announced that it expects to receive KRW 12.2122 billion in funding from Chong Kun Dang Pharmaceutical Corp. AbClon Inc. announced a private placement to issue 1,400,000 shares at an issue price of KRW 8723 for gross proceeds of KRW 12,212,200,000 on May 9, 2025. The transaction includes participation from Chong Kun Dang Pharmaceutical Corp. for 1,400,000 shares. New Risk • Mar 21
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 34% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Revenue is less than US$5m (₩2.4b revenue, or US$1.6m). Market cap is less than US$100m (₩141.6b market cap, or US$96.9m). Aankondiging • Mar 07
AbClon Inc., Annual General Meeting, Mar 31, 2025 AbClon Inc., Annual General Meeting, Mar 31, 2025, at 10:00 Tokyo Standard Time. Location: seminar room, guro-gu, seoul South Korea Aankondiging • Oct 29
AbClon Inc. announced that it expects to receive KRW 30.999884504 billion in funding from The Korea Securities Finance Corporation, Mirae Asset Securities Co., Ltd., KB Securities Co.,Ltd, Shinhan Bank, GC Tech Company Limited and another investor AbClon Inc announced a private placement to issue convertible bonds for gross proceeds KRW 20,000,000,000 and 677,166 common shares at price KRW16,244 for gross proceeds KRW 10,999,884,504, for aggregate gross proceeds KRW 30,999,884,504 on October 28, 2024. The notes bear zero interest and matures on November 29, 2029 for Conversion Period starts from November 29, 2025 to October 29, 2029. The transaction is expected to close on November 29, 2024. The transaction includes participation from Mirae Asset Securities Co., Ltd, KB Securities Co., Ltd, NH Investment & Securities Co., Ltd, The Korea Securities Finance Corporation, Shinhan Bank, GC Tech Company Limited and Dayli Bio Healthcare No.6 Start-Up Venture Private Equity Fund Co., Ltd. The transaction was approved by board of directors. The transaction is expected to close on November 29, 2024. New Risk • May 21
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩13b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩13b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 41% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (7.0% increase in shares outstanding). Revenue is less than US$5m (₩2.6b revenue, or US$1.9m). New Risk • Mar 19
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 41% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (7.2% increase in shares outstanding). Revenue is less than US$5m (₩3.0b revenue, or US$2.2m). New Risk • Jun 10
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 45% per year over the past 5 years. Minor Risk Revenue is less than US$5m (₩3.5b revenue, or US$2.7m). Aankondiging • Sep 30
AbClon Inc. announced that it has received KRW 11.999976975 billion in funding from Quad Investment Management Corp. On September 28, 2022, AbClon Inc. closed the transaction. Reported Earnings • Nov 17
Third quarter 2021 earnings released: ₩117 loss per share (vs ₩81.00 loss in 3Q 2020) The company reported a poor third quarter result with increased losses, weaker revenues and weaker control over costs. Third quarter 2021 results: Revenue: ₩680.0m (down 3.9% from 3Q 2020). Net loss: ₩1.79b (loss widened 68% from 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 59 percentage points per year, which is a significant difference in performance. Aankondiging • Feb 25
AbClon Inc., Annual General Meeting, Mar 29, 2021 AbClon Inc., Annual General Meeting, Mar 29, 2021, at 10:00 Korea Standard Time. Is New 90 Day High Low • Feb 24
New 90-day low: ₩27,600 The company is down 5.0% from its price of ₩28,950 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 7.0% over the same period. Is New 90 Day High Low • Dec 21
New 90-day high: ₩37,250 The company is up 3.0% from its price of ₩36,000 on 22 September 2020. The South Korean market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 10.0% over the same period. Is New 90 Day High Low • Nov 11
New 90-day low: ₩27,350 The company is down 26% from its price of ₩36,750 on 13 August 2020. The South Korean market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 5.0% over the same period. Is New 90 Day High Low • Oct 16
New 90-day low: ₩30,650 The company is down 14% from its price of ₩35,450 on 17 July 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period. Is New 90 Day High Low • Sep 24
New 90-day low: ₩31,800 The company is down 20% from its price of ₩39,800 on 26 June 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 4.0% over the same period. 